Skip to main content

Moderna, Inc. stock price and financials

  • MRNA · Nasdaq
  • Biotechnology
  • S&P 500
$223.37−3.45%Close 13 Nov 2026
Beta · 1 year
2.37
Return · 1 year
+736%
52-week range$22.28 — $280.80

Share price close 16 Nov 2026

−8.7%1 monthHigh $269.00Low $198.85
$180$200$220$240$260$280Q3 FY2026 report filed 6 Nov 202623 Oct29 Oct4 Nov10 Nov16 Nov
+340%6 monthsHigh $269.00Low $45.64
$0$100$200$300Q2 FY2026 report filed 31 Jul 2026Q3 FY2026 report filed 6 Nov 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+632%year to dateHigh $269.00Low $30.86
$0$100$200$300Q4 FY2025 report filed 20 Feb 2026Q1 FY2026 report filed 1 May 2026Q2 FY2026 report filed 31 Jul 2026Q3 FY2026 report filed 6 Nov 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+771%1 yearHigh $269.00Low $22.36
$0$100$200$300Q4 FY2025 report filed 20 Feb 2026Q1 FY2026 report filed 1 May 2026Q2 FY2026 report filed 31 Jul 2026Q3 FY2026 report filed 6 Nov 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+183%3 yearsHigh $269.00Low $22.36
$0$100$200$300Q4 FY2023 report filed 23 Feb 2024Q1 FY2024 report filed 2 May 2024Q2 FY2024 report filed 1 Aug 2024Q3 FY2024 report filed 7 Nov 2024Q4 FY2024 report filed 21 Feb 2025Q1 FY2025 report filed 1 May 2025Q2 FY2025 report filed 1 Aug 2025Q3 FY2025 report filed 6 Nov 2025Q4 FY2025 report filed 20 Feb 2026Q1 FY2026 report filed 1 May 2026Q2 FY2026 report filed 31 Jul 2026Q3 FY2026 report filed 6 Nov 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26

Quarterly or annual report filed

In one paragraph

Moderna, Inc. reported revenue of $1.94 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), down 39.9% from fiscal 2024. Net income was −$2.82 billion and diluted earnings per share −$7.26.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $1.31 billion, up 29.2% from a year earlier.

Figures from Moderna, Inc.'s annual and quarterly reports, compiled and checked by AapWire. Latest report filed 6 Nov 2026.

Revenue FY2025
$1.94B−39.9%
Net income
−$2.82B
Diluted EPS
−$7.26
Gross margin
55.3%+0.6 pts
Free cash flow
−$2.06B
Net cash
$5.13B

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
−$5B$0$5B$10B$15B$20BRevenue, FY16: $108.4MNet income, FY16: −$216.21MFY16Revenue, FY17: $205.82MNet income, FY17: −$255.92MFY17Revenue, FY18: $135.07MNet income, FY18: −$384.73MFY18Revenue, FY19: $60.21MNet income, FY19: −$514MFY19Revenue, FY20: $803MNet income, FY20: −$747MFY20Revenue, FY21: $18.47BNet income, FY21: $12.2BFY21Revenue, FY22: $19.26BNet income, FY22: $8.36BFY22Revenue, FY23: $6.85BNet income, FY23: −$4.71BFY23Revenue, FY24: $3.24BNet income, FY24: −$3.56BFY24Revenue, FY25: $1.94BNet income, FY25: −$2.82BFY25

Latest quarter · Q3 FY2026 to 30 Sep 2026, filed 6 Nov 2026 · Full results →

Revenue
$1.31B+29.2% on a year
Gross margin
75.8%−3.8 pts on a year
Operating income
$130.0M
Net income
$162.0M
Diluted EPS
$0.38
Free cash flow
−$1.61B

Comparable companies All of Health Care →

Moderna, Inc. beside the other S&P 500 members in Biotechnology, by market value.

Moderna, Inc. and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
ModernaMRNA—−3.4%+736%———
AbbVieABBV$525.9B+0.2%+26.5%+10.7%15.7%51.1
AmgenAMGN$253.8B−0.3%+38.5%+8.2%24.1%27.0
Gilead SciencesGILD$210.2B+0.1%+36.2%+6.5%−12.5%—
BiogenBIIB$37.52B+1.2%+56.9%+2.3%3.4%108.0
IncyteINCY$24.67B−0.6%+11.7%+24.9%6.7%61.2
Regeneron PharmaceuticalsREGN—+0.4%+40.2%———

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
-400%-200%0%200%55.3%-145.2%-158.1%FY16FY19FY22FY25

Moderna, Inc. revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By product

Moderna, Inc. revenue by product, by fiscal year
RevenueFY 2022FY 2023FY 2024
COVID$18.43B$6.67B−63.8%$3.08B−53.8%
Collaboration Arrangement, Including Arrangements With Affiliate$440.0M$83.00M−81.1%$48.00M−42.2%
Licensing and royalty revenue$0.00$0.00$42.00M
Grant revenue$388.0M$94.00M−75.8%$37.00M−60.6%
RSV$0.00$0.00$25.00M
Total revenue$19.26B$6.85B$3.24B

By region

Moderna, Inc. revenue by region, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
United States$6.18B$5.15B−16.6%$1.90B−63.2%$1.78B−5.8%$1.20B−32.8%
Rest of world$5.45B$7.30B+34.0%$3.60B−50.7%$853.0M−76.3%$692.0M−18.9%
Europe$6.85B$6.82B−0.5%$1.35B−80.1%$598.0M−55.9%$53.00M−91.1%
Total revenue$18.47B$19.26B$6.85B$3.24B$1.94B

Financial statements

Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Moderna, Inc. income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$108.4M$205.8M$135.1M$60.21M$803.0M$18.47B$19.26B$6.85B$3.24B$1.94B
Revenue growth—+89.9%−34.4%−55.4%+1234%+2200%+4.3%−64.4%−52.7%−39.9%
Gross profit——$135.1M$60.21M$795.0M$15.85B$13.85B$2.15B$1.77B$1.08B
Operating income−$223.8M−$269.4M−$413.3M−$546.0M−$763.0M$13.30B$9.42B−$4.24B−$3.94B−$3.07B
Net income−$216.2M−$255.9M−$384.7M−$514.0M−$747.0M$12.20B$8.36B−$4.71B−$3.56B−$2.82B
Diluted EPS−$3.79−$4.18−$4.95−$1.55−$1.96$28.29$20.12−$12.33−$9.28−$7.26
Gross margin——100%100%99.0%85.8%71.9%31.5%54.8%55.3%
Operating margin−206%−131%−306%—−95.0%72.0%48.9%−61.9%−122%−158%
Net margin−199%−124%−285%—−93.0%66.1%43.4%−68.8%−110%−145%

Cash flow

Moderna, Inc. cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$66.73M−$331.5M−$330.9M−$459.0M$2.03B$13.62B$4.98B−$3.12B−$3.00B−$1.87B
Capital expenditure$33.14M$58.40M$105.8M$32.00M$68.00M$284.0M$400.0M$707.0M$1.05B$192.0M
Free cash flow$33.59M−$389.9M−$436.6M−$491.0M$1.96B$13.34B$4.58B−$3.83B−$4.05B−$2.06B

Balance sheet and shares

Moderna, Inc. balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$50.08M$134.9M$658.4M$235.9M$2.62B$6.85B$3.21B$2.91B$1.93B$2.60B
Total debt——$0.00$135.9M$237.6M$916.0M$1.20B$1.24B$685.0M$670.0M
Shareholders' equity−$334.8M−$551.4M$1.53B$1.17B$2.56B$14.14B$19.12B$13.85B$10.90B$8.65B
Diluted shares60.7M64.5M81.1M331M381M431M416M382M384M389M

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Moderna, Inc. quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$966.0M$108.0M$142.0M$1.02B$678.0M$389.0M$145.0M$1.31B
Revenue, year on year−65.6%−35.3%−41.1%−45.4%−29.8%+260%+2.1%+29.2%
Gross margin23.5%16.7%16.2%79.6%33.3%−146%35.9%75.8%
Operating income−$1.25B−$1.05B−$907.0M−$260.0M−$857.0M−$1.39B−$815.0M$130.0M
Net income−$1.12B−$971.0M−$825.0M−$200.0M−$826.0M−$1.34B−$782.0M$162.0M
Diluted EPS−$2.90−$2.52−$2.13−$0.51−$2.11−$3.40−$1.97$0.38
Free cash flow$303.0M−$1.15B−$922.0M−$880.0M$891.0M−$692.0M−$563.0M−$1.61B

Operating KPIs

The operating figures Moderna, Inc. reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Moderna, Inc. operating KPIs
KPILatestPeriodChange on a yearRecent periods
COVID revenue$1.2Bquarter to 30 Sep 2026up 28.1%
Stand-ready manufacturing revenue$31.0Mquarter to 30 Sep 2026up 55.0%
RSV revenue$29.0Mquarter to 30 Sep 2026up 1350.0%
Collaboration Arrangement, Including Arrangements With Affiliate revenue$8.0Mquarter to 30 Sep 2026up 14.3%
Grant revenue$1.0Mquarter to 30 Sep 2026down 92.9%
United States revenue$1.2Bfiscal year to 31 Dec 2025down 32.8%
Rest of world revenue$692.0Mfiscal year to 31 Dec 2025down 18.9%
Europe revenue$53.0Mfiscal year to 31 Dec 2025down 91.1%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Moderna, Inc.'s revenue in fiscal 2025?

$1.94 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.

What was Moderna, Inc.'s net income in fiscal 2025?

−$2.82 billion for fiscal year 2025 (the twelve months to 31 Dec 2025).

What were Moderna, Inc.'s diluted earnings per share in fiscal 2025?

−$7.26 for fiscal year 2025 (the twelve months to 31 Dec 2025).

What is Moderna, Inc.'s gross margin?

55.3% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.

What is Moderna, Inc.'s operating margin?

−158% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.

How much free cash flow did Moderna, Inc. generate in fiscal 2025?

−$2.06 billion for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.

Where does Moderna, Inc.'s revenue come from?

In fiscal 2025, by product: Net product sales $1.82B (94%), Stand-ready manufacturing revenue $80.00M (4.1%), Grant revenue $22.00M (1.1%), Collaboration Arrangement, Including Arrangements With Affiliate $13.00M (0.7%), out of $1.94B in all, as stated in its annual report.

In the terminal

Twenty years of Moderna, Inc.'s figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans